DOSAGE INDEX / SINGLE
Mazdutide
Research, reported schedules and supply planning.
Compare Mazdutide GLORY-1, GLORY-2 and US phase 2 results, including weight changes, analysis methods and gastrointestinal tolerability.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
Reported example 1
- Amount
- 2.5–6 mg per week; a separate example reaches 10 mg
- Frequency
- Once weekly
- Cycle / observation period
- At least 8–12 weeks in its overview
- Route / research model
- Subcutaneous
The 10 mg vial page gives a different main upper amount. Trial schedules require separate verification.
Reported example 2
- Amount
- 2.5–5 mg per week; a separate example reaches 10 mg
- Frequency
- Once weekly
- Cycle / observation period
- At least 8–12 weeks in its overview
- Route / research model
- Subcutaneous
The 5 mg vial page gives 6 mg as its main upper amount. These summaries preserve that source difference.
Titration & progression
A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.
Vial comparison
No single complete schedule is resolved for this entry. Enter a documented total to compare strengths; the calculator does not select a regimen.
| Vial strength | Vials needed |
|---|---|
| 5 mg | Enter a total |
| 10 mg | Enter a total |
Enter a positive material total.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
- GLORY-1 randomized 610 adults in China to 4-mg Mazdutide, 6-mg Mazdutide or placebo for 48 weeks. At the 32-week primary assessment, mean weight changes were −10.09%, −12.55% and +0.45%, respectively. Its treatment-policy estimand considered outcomes regardless of early treatment discontinuation or initiation of another obesity therapy. At 48 weeks, the corresponding changes were −11.00%, −14.01% and +0.30%. Gastrointestinal events predominated; adverse-event discontinuation was 1.5%, 0.5% and 1.0%. Innovent funded the study. [1]
- GLORY-2 assigned 462 Chinese adults with obesity to Mazdutide or placebo; 461 received treatment and entered the reported analyses. Approximately 16% had type 2 diabetes. At 60 weeks, the 9-mg arm had a mean weight change of −16.65%, compared with −1.50% for placebo. Treatment discontinuation due to adverse events occurred in 2.9% versus 0%. Vomiting, nausea and diarrhea were common, and most events were mild or moderate. Both groups received diet and activity support. [2]
- The US study randomized 179 adults without type 2 diabetes. Its 32-week primary analysis used an efficacy, or hypothetical, estimand. Mean weight changes were −7.3% in the 3-to-6-mg program, −15.6% in the 10-mg arm and −18.1% in the 16-mg arm, versus −0.9% with placebo. The lowest-dose program had not escalated to 6 mg before that assessment. Adverse-event discontinuation was highest in the 16-mg group at 20%, mainly associated with gastrointestinal disorders. Eli Lilly funded the study. [3]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 22 entries mapped from 2 source pages. Medical and supporting references are retained below; supplier entries are excluded.
- Original GLORY-1 report
- Original GLORY-2 report
- US original report
- EClinicalMedicine (PubMed)Further reading · Listed in reference bibliography.
- Nature CommunicationsFurther reading · Listed in reference bibliography.
- New England Journal of MedicineFurther reading · Listed in reference bibliography.
- Diabetes Care (PubMed)Further reading · Listed in reference bibliography.
- Frontiers in EndocrinologyFurther reading · Listed in reference bibliography.
- International Journal of Obesity (Nature)Further reading · Listed in reference bibliography.
- CDCGeneral guidance · Listed in reference bibliography.
- CDCNo destination link supplied in the source bibliography.Further reading · Listed in reference bibliography.
- NCBI BookshelfFurther reading · Listed in reference bibliography.
- New England Journal of Medicine (GLORY-1 PDF) Full phase 3 report with the exact 4 mg and 6 mg target schedules and 48-week study durationFurther reading · Listed in reference bibliography.
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.